Abstract: Alisertib (MLN8237) is a highly selective, orally bioavailable small-molecule inhibitor of Aurora A kinase that has been extensively investigated across various solid and hematological malignancies. In the context of Peripheral T-Cell Lymphoma (PTCL), alisertib demonstrated encouraging single-agent activity in early-phase clinical trials, leading to a global Phase 3 registration-enabling study. Although this Phase 3 trial was discontinued after an interim analysis revealed it was unlikely to achieve superior progression-free survival compared to standard-of-care therapies, the drug's single-agent efficacy was confirmed. To overcome current clinical limitations, research has pivoted toward combination strategies, notably with histone deacetylase (HDAC) inhibitors like romidepsin, which exhibit synergistic antitumor activity by inducing cytokinesis failure in T-cell lymphoma models. Furthermore, novel structural applications of alisertib, such as its incorporation into Proteolysis Targeting Chimeras (PROTACs), offer promising avenues for future therapeutic development. This review synthesizes the pharmacological activity, molecular mechanisms, structure-activity relationships, limitations, and future perspectives of alisertib with a specific focus on its application in PTCL.
1. Introduction
Aurora A kinase is a critical serine/threonine kinase that orchestrates numerous cellular activities during mitosis, including centrosome maturation, spindle formation, and mitotic entry [2]. The amplification and overexpression of the Aurora A gene are frequently observed in a diverse array of cancer types and are strongly correlated with genomic instability, oncogenesis, and poor patient prognosis [1]. Consequently, Aurora A has emerged as an attractive therapeutic target in oncology.
Alisertib (MLN8237) is an investigational, orally administered, selective small-molecule inhibitor of Aurora A kinase [1]. It has been evaluated in multiple clinical trials as both a single agent and in combination regimens for various solid tumors and hematological malignancies [1]. Among hematological cancers, Peripheral T-Cell Lymphoma (PTCL)—a heterogeneous and aggressive group of non-Hodgkin lymphomas—has been a significant research direction for alisertib due to the promising response rates observed in early clinical evaluations [1].
2. Pharmacological Activity
Alisertib has demonstrated notable pharmacological activity in hematological malignancies, particularly in PTCL. In an initial Phase 2 trial evaluating alisertib in various hematological cancers, the overall response rate (ORR) was 27%, which included a 50% ORR (4 out of 8 patients) specifically in the PTCL cohort [1]. Subsequent data from a Phase 2 study led by the South West Oncology Group (SWOG) in patients with PTCL reported an ORR of 24%, comprising two complete responses and seven partial responses. Among the most common PTCL subtypes (PTCL NOS, AITL, and ALCL), the ORR was even higher at 33%, with some responding patients maintaining therapy for over a year [1].
Based on these encouraging Phase 2 results, a global Phase 3, randomized trial (NCT01482962) was initiated to compare alisertib against the investigator’s choice of standard therapies (gemcitabine, pralatrexate, or romidepsin) in patients with relapsed or refractory PTCL [1] [2]. However, this study was discontinued following a pre-specified interim analysis, which indicated that alisertib was unlikely to meet the primary endpoint of superior progression-free survival (PFS) over the standard of care, despite confirming its single-agent activity and demonstrating an ORR similar to the control arm [1] [2].
To enhance efficacy, preclinical studies have supported combining alisertib with HDAC inhibitors like romidepsin, which is already approved for PTCL. Experimental models of T-cell lymphoma showed that alisertib exhibits synergistic antitumor activity when combined with romidepsin, providing a strong rationale for ongoing Phase 1/2 combination trials (e.g., NCT01897012) in relapsed/refractory aggressive B- and T-cell lymphomas [1] [2].
3. Molecular Mechanism of Action
Alisertib functions by selectively binding to and inhibiting the catalytic activity of Aurora A kinase. In cellular models, this inhibition results in delayed mitotic entry and disrupted progression through mitosis, leading to an accumulation of cells with a tetraploid (4N) DNA content [1]. Mitotic cells treated with alisertib exhibit severe structural defects, including monopolar, bipolar, and multipolar spindles with misaligned chromosomes [1]. These defects force the cells to undergo apoptosis directly from mitosis, experience aneuploid cytokinesis, or exit mitosis without cytokinesis (mitotic slippage), ultimately resulting in gross nuclear defects like micronucleation and multinucleation followed by cell death or senescence [1].
In the specific context of T-cell lymphoma, the synergistic mechanism between alisertib and the HDAC inhibitor romidepsin is driven by the induction of cytokinesis failure. This failure is molecularly confirmed by a post-treatment increase in the levels of CENP-A, a chromatin-associated protein that plays a critical role in the final stages of cytokinesis [1]. Furthermore, HDAC inhibitors are known to reduce Aurora A expression, which compounds the pharmacological inhibition provided by alisertib, leading to G2/M cell cycle arrest, abnormal mitotic spindles, and enhanced apoptosis [1].
4. Structure-Activity Relationship (SAR)
Alisertib is characterized structurally as a benzazepine-containing small molecule [1]. It is an ATP-competitive inhibitor that binds to the catalytic domain of Aurora A kinase [1] [2]. This binding not only inhibits the kinase's catalytic function but also induces an allosteric conformational shift in the Aurora A protein. This specific allosteric shift disrupts Aurora A's protein-protein interactions, such as its protective binding to N-Myc, which normally prevents N-Myc degradation by the FBXW7 E3 ubiquitin ligase [1]. Alisertib exhibits extreme selectivity, proving to be >200-fold more potent against Aurora A compared to the structurally related Aurora B kinase in cellular assays [1].
Recent advancements in SAR have utilized the alisertib scaffold to develop Proteolysis Targeting Chimeras (PROTACs). By linking alisertib via ethylene glycol amides to an E3-ubiquitin CEREBLON-binding moiety (such as thalidomide or pomalidomide), researchers have created bifunctional degraders (e.g., JB170) [2]. These PROTACs successfully induce the ubiquitination and subsequent proteasomal degradation of the Aurora A protein itself. Notably, this PROTAC-mediated depletion does not require the catalytic activity of Aurora A, allowing it to eliminate both the kinase and scaffold functions of the protein, thereby overcoming some limitations of traditional ATP-competitive inhibition [2].
5. Current Limitations
Despite its targeted mechanism, the clinical utility of alisertib faces several limitations. Foremost is its clinical efficacy as a monotherapy in advanced stages; as demonstrated in the Phase 3 PTCL trial, alisertib failed to show superiority in progression-free survival over existing standard-of-care agents [1] [2].
Additionally, alisertib is associated with significant treatment-emergent adverse events, primarily reflecting its mechanism as a cell cycle inhibitor in highly proliferative tissues. Myelosuppression—specifically neutropenia, thrombocytopenia, anemia, and leukopenia—is the most common dose-limiting toxicity (DLT) requiring dose reductions [1] [6]. Other frequent adverse effects include gastrointestinal issues (mucositis, stomatitis, diarrhea, nausea, anorexia) and fatigue [1]. Furthermore, patients frequently experience somnolence and mood alterations, which are likely attributable to the benzodiazepine-like chemical structure of the alisertib molecule [1].
6. Future Perspectives
The future clinical development of alisertib in PTCL and other cancers relies heavily on rational combination strategies and precision medicine. Because Aurora A is implicated in resistance to multiple chemotherapies and targeted agents, combining alisertib with drugs that have non-overlapping toxicities—such as the HDAC inhibitor romidepsin—holds significant promise for achieving synergistic efficacy while maintaining an acceptable risk/benefit profile [1].
Moreover, the identification of predictive biomarkers is crucial. Correlative studies are ongoing to identify patient populations most likely to respond to Aurora A inhibition, which could rescue the clinical viability of alisertib by restricting its use to genetically or molecularly susceptible tumor profiles [1]. Finally, the evolution of alisertib into PROTAC degraders represents a cutting-edge therapeutic frontier. By degrading the Aurora A protein entirely rather than merely inhibiting its kinase domain, these novel compounds may bypass acquired resistance mechanisms and provide deeper, more durable anti-tumor responses [2].
